Navigation Links
The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
Date:7/31/2008

en established.

In March 2008, The Quigley Corporation completed the sale of its wholly owned subsidiary, Darius International Inc. ("Darius"), which constituted the Health and Wellness segment, to InnerLight Holdings, Inc. Net loss of the Company for the six months ended June 30, 2008 reflects results from discontinued operations associated with the sale of Darius that included a gain on disposal of $737,000 and income from discontinued operations of $139,000, totaling $876,000 as compared to a loss from discontinued operations of $390,000 for the same period in 2007.

At the end of the second quarter, The Quigley Corporation was added to the Russell Microcap(R) Index, membership in which remains in place for one year and garners automatic inclusion in the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and an industry-leading $4.4 trillion in assets are currently benchmarked to them.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY,

SOURCE Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
2. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
3. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
4. CorVel Corporation Announces Earnings Release Webcast
5. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
6. Webcast Alert: Neogen Corporation Announces Year-End Results
7. PURE Bioscience Announces Distribution Agreement With Orchem Corporation
8. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
9. Genaera Corporation Elects Paul K. Wotton to Board of Directors
10. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
11. U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporations New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...GA,ON,Nov.23/PRNewswire-FirstCall/-YMBioSciencesIn...lopmentcompanythatidentifiesandadvancesadiversepor...agesofdevelopment,todayreportedthatCytopia(ASX:CYT...CYT387,apotent,orally-administeredJAK1/JAK2inhibit...,Minnesota.AproposaltomergeCytopiaintoYMhasbeenpre...
(Date:11/23/2009)...C,Nov.23/PRNewswire/-InimexPharmaceuticals,Inc.ann...sitsPresidentandCEO. ,, Abramsbringsmorethan25y...x.Heisaco-inventorofthenuclearmedicineimagingagent...y,plcwherehewasManager,BiomedicalResearchWorldwide...y,BCandwasPresidentandCEOfrom1996to2006.AnorMEDdis...
(Date:11/20/2009)... , , , , , , , ... AUDIO: , A team of scientists from Washing...zona, Cold Spring Harbor Laboratory and Iowa State...n. The... , , Click here for more... , , , , , , , ...
(Date:11/20/2009)...VILLE, Md., Nov. 20 Nova... has priced an underwritten public offering of 6,8...e public of $3.30 per share. The approximately $2...erwriting discounts and commissions, will be used ... VLP-based vaccines, internal research and develop...
Breaking Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Novavax Prices Public Offering of Common Stock 2
...e Board of,Directors of Shire plc (LSE: SHP) (NASD...al company, announces today that Michael Rosenblat...ctor with immediate effect., Dr Rosenblatt is the...n, Massachusetts. He was previously Professor of M...n senior research positions at the Beth,Israel Dea...
...,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announ...ical Officer of BioMarin, will present a,company u...ugged Conference,in Key Biscayne, Florida on Thurs...ties may access a live audio webcast of the presen...bsite, http://www.BMRN.com . A,replay of the pres...
...r,BioTherapeutics, Inc. (OTC Bulletin Board: CVBTE...rey Jr. to form Cardio Derma Clinical Partners,(CD...general partner, will,fund a minimum of $1,000,000...of CVBT,s wound healing drug candidate., "R&D Par...by some of,today,s biggest names in biotechnology ...
Other Biology Technology:Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4BioMarin to Present at the Morgan Stanley Healthcare Conference 2CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership 2CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership 3
(Date:11/23/2009)... Hampshire microbiologist Louis Tisa has received ...ing of the actinorhizal plants, widespread woody p...ontaminated soils. , The United States Departme... of molecular, cellular and biomedical sciences, $...een the bacteria Frankia and Casuarina, an actinor...
(Date:11/23/2009)... , , , , , , , ... Dr Andrew Marshall, from the Environment Departme...ery of Kinyongia magomberae and his wider work i...re information. , , , , , ... , , , , , , A new species of chamel...
(Date:11/23/2009)...ector of the Interuniversity Professorship in Law ... University of the Basque Country. The Professorsh...r experts such as researchers in the fields of mol...thics. , The Interuniversity Professorship in La...sto and the Basque Country was created in 1993. Th...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research and legislation should go hand in hand, as much as possible 2Stryker Announces Agreements To Acquire Assets 6148 1Stryker Announces Agreements To Acquire Assets 6148 2Stryker Announces Agreements To Acquire Assets 6148 3Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17 6146 1Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 1Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 2Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 3Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 4Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 5Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 6
...by a University of Houston professor will be featu... Summit Research Conference July 28. , Kurt L. Kra...istry at UH, will give a presentation at 11 a.m. o...." , Sponsored by the Nanotechnology Foundation o...or Texas natural science, engineering and medical ...
...have identified a previously unknown family of vir... for the plague especially efficient at killing it...trated that the use of the common roundworm is a v...pestis, the bacterium that causes plague. They als...d the worm is quite similar to what occurs in mamm...
...have identified a previously unknown family of vir... for the plague especially efficient at killing it...trated that the use of the common roundworm is a v...pestis, the bacterium that causes plague. They als...d the worm is quite similar to what occurs in mamm...
Other Biology News:Disease diagnosis, bioengineering covered at state nano summit 2New Look at DNA Hints at Origin of UV Damage 2New Look at DNA Hints at Origin of UV Damage 3New Look at DNA Hints at Origin of UV Damage 4Novel plague virulence factor identified 2Novel plague virulence factor identified 3Novel plague virulence factor identified 4
...far-infrared range FT-IR spectrometers give you th...lass. Yet all this comes at an amazingly affordabl...ving a larger and faster mirror closer to the sour...300%,larger solid angle of energy into the interfe...
... measure three fluorescence lifetimespicoseconds t...es. To match the absorption maxima of the amino ac...xcitation source is the powerful NanoLED-17, a pul...han is widely used as a probe of protein structure...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
Biology Products: